Acorda Therapeutics (ACOR.Q) Hisse Özeti

A biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. Daha fazla detay

ACOR.Q temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	0/6
Temettüler	0/6

Risk Analizi

Negatif hissedar öz sermayesi

1 yıldan az nakit akışı var

Son 3 ayda hisse senedi fiyatı US piyasasına kıyasla oldukça dalgalı

Anlamlı bir piyasa değeri yok ( $37K )

ACOR.Q Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Acorda Therapeutics, Inc. Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Acorda Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.02
52 Haftanın En Yüksek Seviyesi	US$18.00
52 Haftanın En Düşük Seviyesi	US$0.013
Beta	1.69
1 Aylık Değişim	-84.62%
3 Aylık Değişim	-96.88%
1 Yıllık Değişim	-99.88%
3 Yıllık Değişim	-99.97%
5 Yıllık Değişim	-99.99%
Halka arzdan bu yana değişim	-100.00%

Son Haberler & Güncellemeler

Recent updates

Analiz Makalesi • Feb 21

Health Check: How Prudently Does Acorda Therapeutics (NASDAQ:ACOR) Use Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Analiz Makalesi • Dec 18

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Surges 53% Yet Its Low P/S Is No Reason For Excitement

Acorda Therapeutics, Inc. ( NASDAQ:ACOR ) shareholders are no doubt pleased to see that the share price has bounced 53...

Analiz Makalesi • Jun 05

Is Acorda Therapeutics (NASDAQ:ACOR) Using Debt Sensibly?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Seeking Alpha • Oct 17

Acorda wins $16.5M in Ampyra arbitration case with Alkermes

Acorda Therapeutics (NASDAQ:ACOR), a biotech focused on neurological disorders, announced Sunday that a panel of arbitrators awarded it $16.5M from Alkermes (ALKS) in connection with a licensing dispute between the two over multiple sclerosis therapy Ampyra. ACOR shares added ~46% pre-market on Monday in reaction to the news. The decision comes after ACOR sought the intervention of the American Arbitration Association in July 2020 following a dispute with ALKS with the expiration of an Ampyra patent in 2018. The ruling requires ALKS to pay $15M to cover past royalties and $1.5M as prejudgment interest to ACOR. In addition, ACOR will be free to use alternative supplies of Ampyra and will not have to pay ALKS any royalties on net sales for licensing and supplies. Also known as dalfampridine, Ampyra is marketed as Fampyra outside the U.S. by Biogen (BIIB). The extended-release tablet formulation is indicated in the U.S. to improve walking in adults with multiple sclerosis. In 2021, ACOR generated $84.6M of net revenue from Ampyra in the U.S.

Seeking Alpha • Oct 10

Acorda stock rise 11% as proposal to increase shares withdrawn; reverse split still on vote

Acorda Therapeutics (NASDAQ:ACOR) said it withdrew a proposal requesting to increase the number of company's authorized shares. The company is scheduled to hold a special meeting of stockholders on Nov. 4, where several proposals would be put to vote. Meanwhile, a proposal for authorization of a reverse stock split remains on the ballot and the board has asked the shareholders to vote in favor of the request, the company said in an Oct. 10 press release. "However, the proposal to implement a reverse split of Acorda's stock remains critical to ensure that we can get the stock price above $1.00, which would prevent the company from being delisted by Nasdaq. If that were to occur, we could be in default on our obligations to our debtholders and may be required to declare bankruptcy or liquidate, which would be adverse to the interests of shareholders and patients," said Acorda's President and CEO Ron Cohen. ACOR +10.81% to $0.41 premarket Oct. 10

Seeking Alpha • Aug 29

Acorda inks license deal with Asieris for pre-clinical drug

Commercial-stage biopharmaceutical company Acorda Therapeutics (NASDAQ:ACOR) announced a license agreement with Chinese biotech Asieris Pharmaceuticals on Monday for the preclinical candidate, Nepicastat. Per the terms, the two companies will collaborate to develop Nepicastat, a small molecule drug for non-psychiatric indications and therapeutic uses. In return, Acorda (ACOR) is set to receive $500K of upfront payment, up to $7M of fees based on regulatory milestones, and a royalty on future net sales. Acorda (ACOR) U.S. subsidiary, Biotie Therapies, Inc., owns the rights for Nepicastat. Read: In June, the nano-cap ACRO stock surged in reaction to the launch of its inhalational Parkinson’s disease drug Inbrija in Germany. However, the company shares remain ~90% below the year-ago level, as indicated in this graph.

Seeking Alpha • Aug 19

Acorda Therapeutics announces resignation of COO

Acorda Therapeutics (NASDAQ:ACOR) has announced that Lauren Sabella, Chief Operating Officer, will resign from the Co. effective Sept. 30, 2022. Ms. Sabella will be working in a strategic advisory role for early-stage biotechnology companies. Ms. Sabella’s responsibilities will be assumed by two of her current direct reports, Sofia Ali, Senior VP, Operations & Strategic Planning and Susan Way, Senior VP, Drug Development and Regulatory Affairs. ACOR +4.35% premarket to $0.48.

Seeking Alpha • Oct 04

Acorda Therapeutics: Managing The Transition

Today, we take our first look at Acorda Therapeutics which has two approved products on the market. One of these is seeing increasing generic competition while the other is ramping up sales. The company recently announced a significant workforce reduction to reduce costs. Can Acorda manage this transition without diluting shareholders? A full investment analysis follows in the paragraphs below.

Seeking Alpha • Jul 24

Acorda Therapeutics Continues To Maneuver For A Turnaround

Acorda Therapeutics continues to maneuver to set up for a potential turnaround in the coming years. The company recently announced a commercial partnership with Esteve Pharmaceuticals for INBRIJA in Spain. I expect additional European and Ex-U.S. partnerships are on the docket. Acorda was able to remove their debt that was due in 2021. Now, with that overhang removed, any progress made should be reflected in the share price. I update my plan for trading Acorda over the remainder of 2021 as we wait for the remaining quarterly earnings.

Analiz Makalesi • May 26

Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now

The underwhelming share price performance of Acorda Therapeutics, Inc. ( NASDAQ:ACOR ) in the past three years would...

Analiz Makalesi • Mar 09

Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Sole Analyst Just Made A Huge Upgrade To Their Forecasts

Acorda Therapeutics, Inc. ( NASDAQ:ACOR ) shareholders will have a reason to smile today, with the covering analyst...

Hissedar Getirileri

	ACOR.Q	US Biotechs	US Pazar
7D	-28.5%	-1.9%	-4.1%
1Y	-99.9%	23.6%	20.6%

Getiri vs. Endüstri: ACOR.Q geçen yıl % 23.6 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: ACOR.Q geçen yıl % 20.6 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is ACOR.Q's price volatile compared to industry and market?
ACOR.Q volatility
ACOR.Q Average Weekly Movement	55.6%
Biotechs Industry Average Movement	10.6%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: ACOR.Q hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.

Zaman İçindeki Volatilite: ACOR.Q 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 34% dan 56% a yükseldi.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1995	102	Ron Cohen	www.acorda.com

Acorda Therapeutics, Inc. Temel Bilgiler Özeti

Acorda Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ACOR.Q temel i̇stati̇sti̇kler
Piyasa değeri	US$37.39k
Kazançlar(TTM)	-US$263.42m
Gelir(TTM)	US$115.66m

0.0x

P/S Oranı

0.0x

F/K Oranı

ACOR.Q aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ACOR.Q gelir tablosu (TTM)
Gelir	US$115.66m
Gelir Maliyeti	US$20.48m
Brüt Kâr	US$95.19m
Diğer Giderler	US$358.61m
Kazançlar	-US$263.42m

Son Raporlanan Kazançlar

Mar 31, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-212.08
Brüt Marj	82.30%
Net Kâr Marjı	-227.75%
Borç/Özkaynak Oranı	-103.1%

ACOR.Q uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/08/13 08:34
Gün Sonu Hisse Fiyatı	2024/08/13 00:00
Kazançlar	2024/03/31
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Acorda Therapeutics, Inc. 20 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Robert LeBoyer	Aegis Capital Corporation
Christopher Raymond	Baird
Kenneth Trbovich	Brean Capital Historical (Janney Montgomery)

Acorda Therapeutics (ACOR.Q) Hisse Özeti

Risk Analizi

Acorda Therapeutics, Inc. Rakipler

Athenex

Peak Bio

Endonovo Therapeutics

International Stem Cell

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.

Acorda Therapeutics Files Form 15

Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.

Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.

Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Delist Acorda Therapeutics's Common Stock from Nasdaq, Effective on May 5, 2024

Acorda Therapeutics Announces Delisting from Nasdaq

Recent updates

First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.

Acorda Therapeutics Files Form 15

Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.

Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.

Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Delist Acorda Therapeutics's Common Stock from Nasdaq, Effective on May 5, 2024

Acorda Therapeutics Announces Delisting from Nasdaq

Acorda Therapeutics, Inc.(OTCPK:ACOR.Q) dropped from NASDAQ Composite Index

Motion for Asset Sale Filed by Acorda Therapeutics, Inc.

Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the Companys assets of Acorda Therapeutics, Inc. for approximately $190 million.

Motion for Joint Administration Filed by Acorda Therapeutics, Inc.

Acorda Therapeutics, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Health Check: How Prudently Does Acorda Therapeutics (NASDAQ:ACOR) Use Debt?

New minor risk - Share price stability

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Surges 53% Yet Its Low P/S Is No Reason For Excitement

Third quarter 2023 earnings released: US$7.16 loss per share (vs US$11.41 loss in 3Q 2022)

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023

Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA

New minor risk - Shareholder dilution

Acorda Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$7.55 loss per share (vs US$55.63 loss in 2Q 2022)

Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Acorda Therapeutics Announces Completion of Reverse Stock Split to Enable the Company to Regain Compliance with the Minimum Closing Price Required to Maintain Continued Listing on the Nasdaq Global Select Market

Is Acorda Therapeutics (NASDAQ:ACOR) Using Debt Sensibly?

Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split to Regain Compliance with the Minimum Closing Price Required to Maintain Continued Listing

First quarter 2023 earnings released: US$0.69 loss per share (vs US$1.85 loss in 1Q 2022)

Acorda Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$3.35 loss per share (vs US$9.79 loss in FY 2021)

Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement

Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)

Acorda wins $16.5M in Ampyra arbitration case with Alkermes

Acorda stock rise 11% as proposal to increase shares withdrawn; reverse split still on vote

Acorda inks license deal with Asieris for pre-clinical drug

Acorda Therapeutics announces resignation of COO

Second quarter 2022 earnings released: US$2.78 loss per share (vs US$2.29 loss in 2Q 2021)

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Third quarter 2021 earnings released: US$2.43 loss per share (vs US$0.92 profit in 3Q 2020)

Acorda Therapeutics: Managing The Transition

Independent Director Barry Greene has left the company

Independent Director Catherine D. Strader has left the company

Second quarter 2021 earnings released: US$2.29 loss per share (vs US$2.19 loss in 2Q 2020)

Acorda Therapeutics Continues To Maneuver For A Turnaround

Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now

First quarter 2021 earnings released: US$3.53 loss per share (vs US$0.81 loss in 1Q 2020)

Analysts increase revenue estimates to US$95.7m

Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Sole Analyst Just Made A Huge Upgrade To Their Forecasts

Full year 2020 earnings released: US$12.32 loss per share (vs US$34.47 loss in FY 2019)

Revenue and earnings beat expectations

Price target lowered to US$19.50

New 90-day high: US$6.70

Analysts increase EPS estimates to -US$2.88

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Acorda Therapeutics, Inc. Temel Bilgiler Özeti

Kazanç ve Gelir

Şirket Analizi ve Finansal Veri Durumu

Veri Kaynakları

Analiz Modeli ve Kar Tanesi

Endüstri ve Sektör Metrikleri